Recognition and treatment of autonomic disturbances in Parkinsons disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 10, 2015, Pages 1189-1203

  Li, Kai ^a   Reichmann, Heinz ^a   Ziemssen, Tjalf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

autonomic dysfunction; cardiovascular; gastrointestinal; Parkinsons disease; pupil; sexual; thermoregulatory; urinary

Indexed keywords

ANTIPARKINSON AGENT;

ANAMNESIS; ANORECTAL DISEASE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COLON DISEASE; DYSAUTONOMIA; DYSPHAGIA; GASTROINTESTINAL SYMPTOM; HEART RATE VARIABILITY; HUMAN; HYPERSALIVATION; PALLIATIVE THERAPY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRESSORECEPTOR REFLEX; REVIEW; SEXUAL DYSFUNCTION; STANDING; STOMACH PARESIS; THERMOREGULATION; URINARY DYSFUNCTION; UROLOGIC EXAMINATION; VALSALVA MANEUVER; AUTONOMIC NERVOUS SYSTEM DISEASES; COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM DISEASES; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942862828     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1095093     Document Type: Review

References (155)

1. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinsons disease. Mov Disord 2012; 27 (1): 54-60
2. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinsons disease. Eur J Neurol 2013; 20 (1): 16-34
3. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinsons disease and are we missing them? Mov Disord 2010; 25 (15): 2493-500
4. Palma JA, Kaufmann H. Autonomic disorders predicting Parkinsons disease. Parkinsonism Relat Disord 2014; 20 (Suppl 1): S94-8
5. Fanciulli A, Strano S, Colosimo C, et al. The potential prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol 2013; 20 (2): 231-5
6. Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinsons disease with dementia. PLoS ONE 2012; 7 (10): e45451
7. Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinsons disease. J Neurol Sci 2010; 289 (1-2): 74-80
8. Benarroch EE. Central autonomic control. In: Primer on the Autonomic Nervous System. In: Robertson D.,. editor. Academic Press; San Diego, USA: 2004. p. 17-28
9. Robert W, Hamill RES. Peripheral autonomic nervous system. In: Primer on the Autonomic Nervous System. In: Robertson D.,. editor. Academic Press; San Diego, USA: 2004
10. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurobiol Aging 2003; 24 (2): 197-211
11. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119 (6): 689-702
12. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014; 29 (8): 1010-18
13. Ikemura M, Saito Y, Sengoku R, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008; 67 (10): 945-53
14. Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinsons disease. Acta Neuropathol 2012; 124 (5): 643-64
15. Alonso A, Huang X, Mosley TH, et al. Heart rate variability and the risk of Parkinson disease: the atherosclerosis risk in communities study. Ann Neurol 2015; 77 (5): 877-83
16. Gilhus NE, Barnes MP, Brainin M. Late (Complicated) Parkinsons Disease. In: European Handbook of Neurological Management. Wiley-Blackwell; Oxford, UK: 2010. p. 237-67
17. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinsons disease. Mov Disord 2011; 26 (Suppl 3): S42-80
18. Stemper B, Beric A, Welsch G, et al. Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 2006; 67 (10): 1781-5
19. Liu KD, Shan DE, Kuo TB, Yang CC. The effects of bilateral stimulation of the subthalamic nucleus on heart rate variability in patients with Parkinsons disease. J Neurol 2013; 260 (7): 1714-23
20. Sverrisdottir YB, Green AL, Aziz TZ, et al. Differentiated baroreflex modulation of sympathetic nerve activity during deep brain stimulation in humans. Hypertension 2014; 63 (5): 1000-10
21. Ludwig J, Remien P, Guballa C, et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinsons disease. J Neurol Neurosurg Psychiatry 2007; 78 (7): 742-5
22. Sumi K, Katayama Y, Otaka T, et al. Effect of subthalamic nucleus deep brain stimulation on the autonomic nervous system in Parkinsons disease patients assessed by spectral analyses of R-R interval variability and blood pressure variability. Stereotact Funct Neurosurg 2012; 90 (4): 248-54
23. Trachani E, Constantoyannis C, Sakellaropoulos GC, et al. Heart rate variability in Parkinsons disease unaffected by deep brain stimulation. Acta Neurol Scand 2012; 126 (1): 56-61
24. Fujishiro H, Frigerio R, Burnett M, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinsons disease. Mov Disord 2008; 23 (8): 1085-92
25. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European society of cardiology and the North American society of pacing and electrophysiology. Circulation 1996; 93 (5): 1043-65
26. Ziemssen T, Reichmann H. Cardiovascular autonomic testing in extrapyramidal disorders. J Neurol Sci 2011; 310 (1-2): 129-32
27. Schmidt C, Berg D, Herting et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 2009; 24 (14): 2136-42
28. Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm 2008; 115 (11): 1527-36
29. Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 2010; 25 (3): 315-24
30. Gasch J, Reimann M, Reichmann H, et al. Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. PLoS ONE 2011; 6 (3): e18061
31. Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol 2014; 4 (2): 805-26
32. Goldstein DS. Orthostatic hypotension as an early finding in Parkinsons disease. Clin Auton Res 2006; 16 (1): 46-54
33. Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008; 18 (Suppl 1): 8-13
34. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The consensus committee of the american autonomic society and the american academy of neurology. Neurology 1996; 46 (5): 1470
35. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011; 21 (2): 69-72
36. Allcock LM, Kenny RA, Burn DJ. Clinical phenotype of subjects with Parkinsons disease and orthostatic hypotension: autonomic symptom and demographic comparison. Mov Disord 2006; 21 (11): 1851-5
37. Suzuki M, Urashima M, Oka H, et al. Cardiac sympathetic denervation in bradykinesia-dominant Parkinsons disease. Neuroreport 2007; 18 (17): 1867-70
38. Kim JS, Lee KS, Song IU, et al. Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J Neurol Sci 2008; 270 (1-2): 122-6
39. Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K. Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinsons disease. J Neurol Sci 2008; 264 (1-2): 22-6
40. Stuebner E, Vichayanrat E, Low DA, et al. Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease. Clin Auton Res 2015; 25 (2): 109-16
41. Oka H, Toyoda C, Yogo M, Mochio S. Olfactory dysfunction and cardiovascular dysautonomia in Parkinsons disease. J Neurol 2010; 257 (6): 969-76
42. Iijima M, Osawa M, Momose M, et al. Cardiac sympathetic degeneration correlates with olfactory function in Parkinsons disease. Mov Disord 2010; 25 (9): 1143-9
43. Kang P, Kloke J, Jain S. Olfactory dysfunction and parasympathetic dysautonomia in Parkinsons disease. Clin Auton Res 2012; 22 (4): 161-6
44. Postuma RB, Montplaisir J, Lanfranchi P, et al. Cardiac autonomic denervation in Parkinsons disease is linked to REM sleep behavior disorder. Mov Disord 2011; 26 (8): 1529-33
45. Nomura T, Inoue Y, Hogl B, et al. Relationship between (123)I-MIBG scintigrams and REM sleep behavior disorder in Parkinsons disease. Parkinsonism Relat Disord 2010; 16 (10): 683-5
46. Jain S, Siegle GJ, Gu C, et al. Autonomic insufficiency in pupillary and cardiovascular systems in Parkinsons disease. Parkinsonism Relat Disord 2011; 17 (2): 119-22
47. Oh YS, Kim JS, Yang DW, et al. Nighttime blood pressure and white matter hyperintensities in patients with Parkinson disease. Chronobiol Int 2013; 30 (6): 811-17
48. Chiaravalloti A, Stefani A, Di Biagio D, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinsons disease. Ann Nucl Med 2013; 27 (5): 444-51
49. Oh YS, Kim JS, Chung YA, et al. Orthostatic hypotension, non-dipping and striatal dopamine in Parkinson disease. Neurol Sci 2013; 34 (4): 557-60
50. Nakamura T, Hirayama M, Hara T, et al. Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinsons disease? Mov Disord 2011; 26 (10): 1869-74
51. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014; 71 (4): 499-504
52. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinsons disease: pre-motor disorders in Parkinsons disease. Mov Disord 2012; 27 (5): 617-26
53. Oguri T, Tachibana N, Mitake S, et al. Decrease in myocardial 123I-MIBG radioactivity in REM sleep behavior disorder: two patients with different clinical progression. Sleep Med 2008; 9 (5): 583-5
54. Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Ann Neurol 2015; 77 (5): 830-9
55. Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015; 84 (11): 1104-13
56. Schmidt C, Herting B, Prieur S, et al. Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm 2009; 116 (7): 875-80
57. Reimann M, Schmidt C, Herting B, et al. Comprehensive autonomic assessment does not differentiate between Parkinsons disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm 2010; 117 (1): 69-76
58. Schmidt C, Herting B, Prieur S, et al. Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord 2008; 23 (14): 2083-9
59. Schmidt C, Herting B, Prieur S, et al. Autonomic dysfunction in different subtypes of multiple system atrophy. Mov Disord 2008; 23 (12): 1766-72
60. Baschieri F, Calandra-Buonaura G, Doria A, et al. Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stage. Parkinsonism Relat Disord 2015; 21 (5): 477-82
61. Pilleri M, Levedianos G, Weis L, et al. Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. Parkinsonism Relat Disord 2014; 20 (2): 217-21
62. Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinsons disease from multiple system atrophy. Neurology 1999; 53 (5): 1020-5
63. Chung EJ, Lee WY, Yoon WT, et al. MIBG scintigraphy for differentiating Parkinsons disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 2009; 24 (11): 1650-5
64. Goldstein DS, Holmes C, Kopin IJ, Sharabi Y. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest 2011; 121 (8): 3320-30
65. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014; 83 (4): 328-35
66. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95 (1): 38-48
67. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group. JAMA 1997; 277 (13): 1046-51
68. Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinsons disease (nOH306B). Mov Disord 2015; 30 (5): 646-54
69. Treatment of orthostatic intolerance in patients with Parkinsons disease using midodrine. Available from: https://clinicaltrials.gov/ct2/show/NCT02365012
70. Durrieu G, Senard JM, Tran MA, et al. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians. Clin Neuropharmacol 1991; 14 (1): 84-90
71. Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinsons disease. J Neurol 2000; 247 (11): 868-74
72. Turkka J, Suominen K, Tolonen U, et al. Selegiline diminishes cardiovascular autonomic responses in Parkinsons disease. Neurology 1997; 48 (3): 662-7
73. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinsons disease. N Engl J Med 2009; 361 (13): 1268-78
74. Parkinson Study G. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62 (2): 241-8
75. Korchounov A, Kessler KR, Schipper HI. Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinsons disease. Acta Neurol Scand 2004; 109 (1): 45-51
76. Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinsons disease. Parkinsonism Relat Disord 2012; 18 (5): 501-5
77. Quadri R, Comino I, Scarzella L, et al. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration. Funct Neurol 2000; 15 (2): 81-6
78. Sriranjini SJ, Ganesan M, Datta K, et al. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinsons disease. Neurol India 2011; 59 (5): 659-63
79. Senard JM, Verwaerde P, Rascol O, Montastruc JL. Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. Hypertens Res 1995; 18 (Suppl 1): S175-7
80. Rocchi C, Pierantozzi M, Pisani V, et al. The impact of rotigotine on cardiovascular autonomic function in early Parkinsons disease. Eur Neurol 2012; 68 (3): 187-92
81. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinsons disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23 (6): 837-44
82. Barichella M, Cereda E, Madio C, et al. Nutritional risk and gastrointestinal dysautonomia symptoms in Parkinsons disease outpatients hospitalised on a scheduled basis. Br J Nutr 2013; 110 (2): 347-53
83. Shannon KM, Keshavarzian A, Dodiya HB, et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinsons disease? Evidence from 3 cases. Mov Disord 2012; 27 (6): 716-19
84. Sanchez-Ferro A, Rabano A, Catalan MJ, et al. In vivo gastric detection of alpha-synuclein inclusions in Parkinsons disease. Mov Disord 2015; 30 (4): 517-24
85. Visanji NP, Marras C, Hazrati LN, et al. Alimentary, my dear Watson? The challenges of enteric alpha-synuclein as a Parkinsons disease biomarker. Mov Disord 2014; 29 (4): 444-50
86. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinsons disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 2010; 5 (1): e8762
87. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinsons disease. Neurobiol Dis 2013; 50: 42-8
88. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinsons disease. PLoS One 2011; 6 (12): e28032
89. Clairembault T, Leclair-Visonneau L, Neunlist M, Derkinderen P. Enteric glial cells: new players in Parkinsons disease? Mov Disord 2015; 30 (4): 494-8
90. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinsons disease. Cochrane Database Syst Rev 2008 (2): CD006564
91. Muller B, Assmus J, Larsen JP, et al. Autonomic symptoms and dopaminergic treatment in de novo Parkinsons disease. Acta Neurol Scand 2013; 127 (4): 290-4
92. Lee WY, Yoon WT, Shin HY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinsons disease. Mov Disord 2008; 23 (12): 1696-700
93. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinsons disease. Neurobiol Dis 2012; 46 (3): 559-64
94. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015; 84 (6): 609-16
95. Kalf JG, de Swart BJ, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinsons disease: a meta-analysis. Parkinsonism Relat Disord 2012; 18 (4): 311-15
96. Pfeiffer RF. Autonomic dysfunction in Parkinsons disease. Expert Rev Neurother 2012; 12 (6): 697-706
97. Park H, Lee JY, Shin CM, et al. Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. Parkinsonism Relat Disord 2015; 21 (5): 455-60
98. Hammer MJ, Murphy CA, Abrams TM. Airway somatosensory deficits and dysphagia in Parkinsons disease. J Parkinsons Dis 2013; 3 (1): 39-44
99. van Hooren MR, Baijens LW, Voskuilen S, et al. Treatment effects for dysphagia in Parkinsons disease: a systematic review. Parkinsonism Relat Disord 2014; 20 (8): 800-7
100. Troche MS, Brandimore AE, Foote KD, Okun MS. Swallowing and deep brain stimulation in Parkinsons disease: a systematic review. Parkinsonism Relat Disord 2013; 19 (9): 783-8
101. Simons JA, Fietzek UM, Waldmann A, et al. Development and validation of a new screening questionnaire for dysphagia in early stages of Parkinsons disease. Parkinsonism Relat Disord 2014; 20 (9): 992-8
102. Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinsons disease. N Engl J Med 2002; 346 (15): 1174-5
103. Silbergleit AK, LeWitt P, Junn F, et al. Comparison of dysphagia before and after deep brain stimulation in Parkinsons disease. Mov Disord 2012; 27 (14): 1763-8
104. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74 (11): 924-31
105. Salat-Foix D, Andrews CN, Meddings J, Suchowersky O. Gastrointestinal symptoms in Parkinson disease: clinical aspects and management. Can J Neurol Sci 2011; 38 (4): 557-64
106. Ziemssen T, Fuchs G, Greulich W, et al. Treatment of dysautonomia in extrapyramidal disorders. J Neurol 2011; 258 (Suppl 2): S339-45
107. Woitalla D, Kassubek J, Timmermann L, et al. Reduction of gastrointestinal symptoms in Parkinsons disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord 2015; 21 (3): 199-204
108. Gil RA, Hwynn N, Fabian T, et al. Botulinum toxin type A for the treatment of gastroparesis in Parkinsons disease patients. Parkinsonism Relat Disord 2011; 17 (4): 285-7
109. Pfeiffer RF. Gastrointestinal dysfunction in Parkinsons disease. Lancet Neurol 2003; 2 (2): 107-16
110. Pagano G, Tan EE, Haider JM, et al. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinsons disease. Parkinsonism Relat Disord 2015; 21 (2): 120-5
111. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinsons disease. Neurology 2001; 57 (3): 456-62
112. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology 2014; 83 (19): 1739-46
113. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinsons disease. A randomized placebo-controlled study. Mov Disord 2007; 22 (9): 1239-44
114. Sakakibara R, Panicker J, Finazzi-Agro E, Parkinsons Disease Subcomittee TNPCiTICS. A guideline for the management of bladder dysfunction in Parkinsons disease and other gait disorders. Neurourol Urodyn 2015
115. Iacovelli E, Gilio F, Meco G, et al. Bladder symptoms assessed with overactive bladder questionnaire in Parkinsons disease. Mov Disord 2010; 25 (9): 1203-9
116. Kim M, Jung JH, Park J, et al. Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinsons disease. Parkinsonism Relat Disord 2015; 21 (3): 205-10
117. Badri AV, Purohit RS, Skenazy J, et al. A review of lower urinary tract symptoms in patients with Parkinsons disease. Curr Urol Rep 2014; 15 (9): 435
118. Brusa L, Musco S, Bernardi G, et al. Rasagiline effect on bladder disturbances in early mild Parkinsons disease patients. Parkinsonism Relat Disord 2014; 20 (8): 931-2
119. Winge K, Nielsen KK, Stimpel H, et al. Lower urinary tract symptoms and bladder control in advanced Parkinsons disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord 2007; 22 (2): 220-5
120. Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinsons disease. Brain 2006; 129 (Pt 12): 3366-75
121. Fritsche HM, Ganzer R, Schlaier J, et al. Acute urinary retention in two patients after subthalamic nucleus deep brain stimulation (STN-DBS) for the treatment of advanced Parkinsons disease. Mov Disord 2009; 24 (10): 1553-4
122. Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinsons disease. Parkinsonism Relat Disord 2015; 21 (5): 514-20
123. A pilot study of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in parkinsons disease (MAESTRO) (Maestro). Available from: https://clinicaltrials.gov/ct2/show/NCT02092181
124. Vaughan CP, Juncos JL, Burgio KL, et al. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011; 76 (19): 1631-4
125. Perissinotto MC, DAncona CA, Lucio A, et al. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Continence Nurs 2015; 42 (1): 94-9
126. Stewart JD. Sexual function. In: Robertson D.,. editor. Primer on the Autonomic Nervous System. Academic Press; San Diego, USA: 2004. p. 116-17
127. Meco G, Rubino A, Caravona N, Valente M. Sexual dysfunction in Parkinsons disease. Parkinsonism Relat Disord 2008; 14 (6): 451-6
128. Solla P, Bortolato M, Cannas A, et al. Paraphilias and paraphilic disorders in Parkinsons disease: A systematic review of the literature. Mov Disord 2015; 30 (5): 604-13
129. Wermuth L, Stenager E. Sexual problems in young patients with Parkinsons disease. Acta Neurol Scand 1995; 91 (6): 453-5
130. Celikel E, Ozel-Kizil ET, Akbostanci MC, Cevik A. Assessment of sexual dysfunction in patients with Parkinsons disease: a case-control study. Eur J Neurol 2008; 15 (11): 1168-72
131. Bronner G, Vodusek DB. Management of sexual dysfunction in Parkinsons disease. Ther Adv Neurol Disord 2011; 4 (6): 375-83
132. Jitkritsadakul O, Jagota P, Bhidayasiri R. Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinsons disease. Parkinsonism Relat Disord 2015; 21 (1): 61-7
133. Wullner U, Schmitz-Hubsch T, Antony G, et al. Autonomic dysfunction in 3414 Parkinsons disease patients enrolled in the German Network on Parkinsons disease (KNP e.V.): the effect of ageing. Eur J Neurol 2007; 14 (12): 1405-8
134. Yamashita S, Uchida Y, Kojima S, et al. Heatstroke in patients with Parkinsons disease. Neurol Sci 2012; 33 (3): 685-7
135. Sehara Y. Hypothermia with Osborn waves in Parkinsons disease. Intern Med 2009; 48 (8): 615-18
136. Mikihiro Kihara JS, Phillip A. Low Temperature regulation. In: Robertson D.,. editor. Primer on the Autonomic Nervous System. Academic Press; San Diego, USA: 2004. p. 127-9
137. Michell AW, Luheshi LM, Barker RA. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinsons disease. Neurosci Lett 2005; 381 (3): 294-8
138. Dabby R, Djaldetti R, Shahmurov M, et al. Skin biopsy for assessment of autonomic denervation in Parkinsons disease. J Neural Transm 2006; 113 (9): 1169-76
139. Doppler K, Ebert S, Uceyler N, et al. Cutaneous neuropathy in Parkinsons disease: a window into brain pathology. Acta Neuropathol 2014; 128 (1): 99-109
140. Zhong G, Bolitho S, Grunstein R, et al. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinsons disease. PLoS One 2013; 8 (8): e72661
141. Giza E, Katsarou Z, Georgiadis G, Bostantjopoulou S. Sympathetic skin response in Parkinsons disease before and after mental stress. Neurophysiol Clin 2012; 42 (3): 125-31
142. Asahina M, Mathias CJ, Katagiri A, et al. Sudomotor and cardiovascular dysfunction in patients with early untreated Parkinsons disease. J Parkinsons Dis 2014; 4 (3): 385-93
143. Kawada M, Tamada Y, Simizu H, et al. Reduction in QSART and vasoactive intestinal polypeptide expression in the skin of Parkinsons disease patients and its relation to dyshidrosis. J Cutan Pathol 2009; 36 (5): 517-21
144. Kikkawa Y, Asahina M, Suzuki A, Hattori T. Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinsons disease. Parkinsonism Relat Disord 2003; 10 (2): 101-6
145. Sanghera MK, Ward C, Stewart RM, et al. Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinsons disease-a case report. J Neurol Sci 2009; 285 (1-2): 246-9
146. McDougal DH, Gamlin PD. Autonomic control of the eye. Compr Physiol 2015; 5 (1): 439-73
147. Schmidt C, Herting B, Prieur S, et al. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord 2007; 22 (14): 2123-6
148. Stergiou V, Fotiou D, Tsiptsios D, et al. Pupillometric findings in patients with Parkinsons disease and cognitive disorder. Int J Psychophysiol 2009; 72 (2): 97-101
149. Sawada H, Yamakawa K, Yamakado H, et al. Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 2005; 293 (8): 932-4
150. Hori N, Takamori M, Hirayama M, et al. Pupillary supersensitivity and visual disturbance in Parkinsons disease. Clin Auton Res 2008; 18 (1): 20-7
151. Granholm E, Morris S, Galasko D, et al. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimers and Parkinsons disease. Int J Psychophysiol 2003; 47 (2): 95-115
152. Jain S, Siegle GJ, Gu C, et al. Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Mov Disord 2011; 26 (7): 1344-7
153. Tijero B, Gomez Esteban JC, Somme J, et al. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat Disord 2013; 19 (10): 906-9
154. Tijero B, Gabilondo I, Lezcano E, et al. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations. Parkinsonism Relat Disord 2015; 21 (7): 717-22
155. Mansfield KJ. Role of fesoterodine in the treatment of overactive bladder. Open Access J Urol 2009; 2: 1-9